Loading...
Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
Hepatitis B virus (HBV) reactivation is well documented in individuals with cancer who receive certain cytotoxic or immunosuppressive therapies including rituximab treatment. As a general rule, the risk is greatest upon withdrawal of chemotherapy. The risk ranges from approximately 20 to 50% among H...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger AG
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3492963/ https://ncbi.nlm.nih.gov/pubmed/23139664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000342913 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|